Broad spectrum triazoles for invasive mould infections in adults: Which drug and when?

Medical Mycology
Jeffrey D JenksMartin Hoenigl

Abstract

Invasive mould infections are an increasing cause of morbidity and mortality globally, mainly due to increasing numbers of immunocompromised individuals at risk for fungal infections. The introduction of broad spectrum triazoles, which are much better tolerated compared to conventional amphotericin B formulations, has increased survival, particularly in invasive mould infection. However, early initiation of appropriate antifungal treatment remains a major predictor of outcome in invasive mould infection, but despite significant advances in diagnosis of these diseases, early diagnosis remains a challenge. As a result, prophylaxis with mould-active triazoles is widely used for those patients at highest risk for invasive mould infection, including patients with prolonged neutropenia after induction chemotherapy for acute myeloid leukemia and patients with graft-versus-host-disease. Posaconazole is the recommended drug of choice for antimould prophylaxis in these high-risk patients. Voriconazole has its primary role in treatment of invasive aspergillosis but not in prophylaxis. Recently, isavuconazole has been introduced as an excellent alternative to voriconazole for primary treatment of invasive aspergillosis in patients with hem...Continue Reading

References

May 29, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ingo K MellinghoffGary J Schiller
Aug 9, 2002·The New England Journal of Medicine·Raoul HerbrechtUNKNOWN Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillu
Mar 11, 2003·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·B P HowdenA M Mijch
Apr 26, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John R PerfectElizabeth Johnson
Dec 21, 2004·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Raoul HerbrechtValérie Letscher-Bru
Dec 27, 2005·Antimicrobial Agents and Chemotherapy·R N GreenbergR Hare
Mar 3, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jo-Anne H van BurikDimitrios P Kontoyiannis
Apr 19, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christopher D PfeifferNasia Safdar
Nov 8, 2006·Antimicrobial Agents and Chemotherapy·Andres PascualOscar Marchetti
Dec 5, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas J WalshJohn R Perfect
Jan 26, 2007·The New England Journal of Medicine·Andrew J UllmannSimon Durrant
Jan 26, 2007·The New England Journal of Medicine·Oliver A CornelyDavid Angulo-Gonzalez
Apr 20, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Oliver A CornelyUNKNOWN AmBiLoad Trial Study Group
Mar 14, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Catherine CordonnierMichaël Schwarzinger
Apr 14, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Roger J M BrüggemannDavid M Burger
Nov 6, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Johan MaertensKatrien Lagrou
Dec 3, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael NeelyJill Hoffman
Jun 11, 2010·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Koji TakemotoKatsunori Kanazawa
Jul 14, 2010·Antimicrobial Agents and Chemotherapy·Olivier LortholaryUNKNOWN French Mycoses Study Group
Aug 13, 2011·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Si-Hyun KimJin-Hong Yoo
Sep 2, 2011·British Journal of Haematology·David I MarksUNKNOWN IMPROVIT Study Group
Nov 9, 2011·Antimicrobial Agents and Chemotherapy·William W Hope
Nov 15, 2011·Journal of Clinical Microbiology·Roxana G VitaleGrit Walther
Apr 7, 2012·International Journal of Antimicrobial Agents·Martin HoeniglRobert Krause
May 23, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andres PascualOscar Marchetti
Jul 4, 2012·Antimicrobial Agents and Chemotherapy·Michael J DoltonAndrew J McLachlan
Aug 15, 2012·Antimicrobial Agents and Chemotherapy·Michael J DoltonAndrew J McLachlan
Aug 18, 2012·The Journal of Infection·William J SteinbachDavid L Horn
Jan 3, 2013·Current Pharmaceutical Design·Martin Hoenigl, Robert Krause
Oct 15, 2013·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M NucciE Anaissie

❮ Previous
Next ❯

Citations

Feb 6, 2020·Journal of Fungi·Matthias EggerJuergen Prattes
Aug 4, 2020·Mycoses·Jeffrey D JenksMartin Hoenigl
Jan 1, 2020·Journal of Fungi·Jeffrey D JenksMartin Hoenigl
Jul 1, 2020·Journal of Fungi·Amir ArastehfarMartin Hoenigl
Sep 26, 2019·Current Fungal Infection Reports·Jeffrey D JenksMartin Hoenigl
Aug 24, 2020·BMC Musculoskeletal Disorders·Guohua DaiShuzhong Li
Dec 17, 2020·The Journal of Antimicrobial Chemotherapy·Marcio NucciLivio Pagano
Jan 28, 2021·Journal of Fungi·Idoia BuldainAndoni Ramirez-Garcia
Jul 29, 2020·Journal de mycologie médicale·K Brunet, B Rammaert
Dec 18, 2020·The Lancet Infectious Diseases·Philipp KoehlerUNKNOWN Infectious Disease Canada
May 27, 2021·Studies in Mycology·A ArastehfarM Hoenigl
Aug 24, 2021·Clinical and Experimental Medicine·Amir AbdoliAzra Kenarkoohi
Sep 17, 2021·Critical Care : the Official Journal of the Critical Care Forum·Stefan HatzlGernot Schilcher
Dec 7, 2021·Microbiology and Immunology·Sofia Marisel Rivelli Zea, Takahito Toyotome
Dec 20, 2021·Therapeutic Drug Monitoring·Benjamin KablyEliane M Billaud

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.